Standout Papers

Design and Endpoints of Clinical Trials in Hepatocellular Carcinoma 2005 2026 2012 2019 1.3k
  1. Design and Endpoints of Clinical Trials in Hepatocellular Carcinoma (2008)
    Josep M. Llovet, Adrian M. Di Bisceglie et al. JNCI Journal of the National Cancer Institute
  2. Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study (2015)
    Joong‐Won Park, Minshan Chen et al. Liver International
  3. Resection and Liver Transplantation for Hepatocellular Carcinoma (2005)
    Josep M. Llovet, Myron Schwartz et al. Seminars in Liver Disease
  4. Recurrence of Hepatocellular Cancer After Resection (2014)
    Parissa Tabrizian, Ghalib Jibara et al. Annals of Surgery
  5. Genome‐wide molecular profiles of HCV‐induced dysplasia and hepatocellular carcinoma† (2007)
    Elisa Wurmbach, Ying‐Bei Chen et al. Hepatology
  6. α-Fetoprotein, Des-γ Carboxyprothrombin, and Lectin-Bound α-Fetoprotein in Early Hepatocellular Carcinoma (2009)
    Jorge A. Marrero, Ziding Feng et al. Gastroenterology
  7. A System of Classifying Microvascular Invasion to Predict Outcome After Resection in Patients With Hepatocellular Carcinoma (2009)
    Sasan Roayaie, Iris Blume et al. Gastroenterology
  8. The role of hepatic resection in the treatment of hepatocellular cancer (2015)
    Sasan Roayaie, Ghalib Jibara et al. Hepatology
  9. Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference (2020)
    Josep M. Llovet, Augusto Villanueva et al. Hepatology
  10. Evidence-Based Management of Hepatocellular Carcinoma: Systematic Review and Meta-analysis of Randomized Controlled Trials (2002–2020) (2021)
    Philipp K. Haber, Marc Puigvehí et al. Gastroenterology
  11. Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma (2024)
    Josep M. Llovet, Roser Pinyol et al. Nature Reviews Clinical Oncology
  12. Ten-Year Outcomes of Liver Transplant and Downstaging for Hepatocellular Carcinoma (2022)
    Parissa Tabrizian, Matthew L. Holzner et al. JAMA Surgery

Immediate Impact

9 by Nobel laureates 3 from Science/Nature 112 standout
Sub-graph 1 of 17

Citing Papers

Immune checkpoint therapy—current perspectives and future directions
2023 StandoutNobel
Hepatocellular carcinoma
2022 Standout
49 intermediate papers

Works of Myron Schwartz being referenced

A pilot study of ultra-deep targeted sequencing of plasma DNA identifies driver mutations in hepatocellular carcinoma
2018
Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study
2015 Standout
and 37 more

Author Peers

Author Last Decade Papers Cites
Myron Schwartz 12616 7299 6754 325 20.3k
Tadatoshi Takayama 11928 7683 6136 478 18.2k
Philip J. Johnson 11341 4277 8348 311 21.0k
Sheung Tat Fan 9481 6933 4991 356 20.2k
Wan Yee Lau 10517 7815 5561 433 18.5k
Luigi Bolondi 12197 4023 8227 272 18.0k
Ken Shirabe 8017 6516 4698 846 16.9k
Laura Kulik 15323 5559 8093 147 19.3k
Chung Mau Lo 8336 6426 4299 341 14.7k
Bruno Sangro 15541 4620 8005 410 24.8k
Fabio Piscaglia 14715 4899 10379 360 20.3k

All Works

Loading papers...

Rankless by CCL
2026